Acute Gout Flares

Title: A Multicenter, Randomized, Double-blind, Active, Controlled Study of the Efficacy and Safety of Rilonacept Administered Subcutaneously for the Treatment of Gout Flares

Institutional Review Board: Copernicus Group

Status

Closed

Phase: 3

Purpose: To determine the safety and efficacy of rilonacept alone or in combination with indomethacin in treating the signs and symptoms of an acute gout flare

Eligibility:

People aged 18 to 75 years who have

• Met preliminary American Rheumatism Association criteria for the classification of acute arthritis of primary gout if any of 6 or more of the 13 criteria are present, serially or simultaneously, during any interval of observation or if monosodium urate monohydrate microcrystals have been identified in a joint
• An acute gout attack within 48 hours of pain onset
• Had pain relief from a nonsteroidal anti-inflammatory drug for a previous gout flare
• Current presentation of acute gout flare in 3 or fewer joints

Principal Investigator: Michael B. Wax, MD

Duration: 31 days, with 4 to 5 visits and 1 telephone interview

Contact: Isabella Rodriguez, PhD
Clinical Research Coordinator

Genevieve Barragan, BA
Clinical Research Coordinator